The Cardiovascular Stack: What Survives the Outcome Trials

The Four That Survive

Omega-3 EPA and DHA, 2 g or more combined. Reliably lowers triglycerides in a dose-dependent way. Outcome trial results are heterogeneous: high-dose purified EPA in patients with elevated triglycerides on statin therapy reduced events, while lower doses of mixed preparations have been largely neutral. Atrial fibrillation risk has been reported at higher doses, which is a genuine consideration.

Soluble fibre, toward 30 g total fibre daily. Lowers LDL modestly and reliably by binding bile acids, improves glycaemic response, and supports Pillar 6. Psyllium and beta-glucan from oats and barley are the practical sources, and this is the best value item in the stack.

Plant sterols and stanols, 2 g daily. Lower LDL cholesterol by 8 to 10 per cent by competing with cholesterol for absorption. Well-established surrogate effect, no outcome trial evidence, and a theoretical concern about sterol accumulation.

Magnesium and potassium, where intake is low. Both associate with lower blood pressure. Potassium should come from food, since supplementation is constrained by safety in anyone with kidney impairment or on ACE inhibitors, ARBs or potassium-sparing diuretics.

That is the list with reasonable support. Two items lower atherogenic particles modestly, one lowers triglycerides substantially, and one supports blood pressure.

The Documented Failures

The niacin and B-vitamin results are the most instructive in supplement science generally. Both moved their target biomarker reliably and neither improved outcomes, which demonstrates that a marker moving is not the same as a benefit. Any recommendation resting on a surrogate rather than an outcome inherits that risk.

The beta-carotene result establishes that supplements can cause harm at doses above dietary intake, which is the strongest argument against megadosing anything on mechanistic grounds.

The Pharmacological Grey Area

Two products sold as supplements behave like drugs and deserve to be handled as such.

Red yeast rice. Contains monacolin K, chemically identical to lovastatin. It lowers LDL because it is a statin, with unpredictable content between products and the same side-effect profile including muscle symptoms and hepatic effects. Regulatory positions vary by jurisdiction. Anyone taking it is taking an unstandardised statin without monitoring, which is a worse version of the licensed option.

Berberine. Reduces fasting glucose, HbA1c and lipids at effect sizes compared to metformin in individual trials. It has poor bioavailability, gastrointestinal effects, and substantial CYP3A4 and P-glycoprotein interactions that matter for anyone on common medications. It warrants a full medication review rather than casual addition.

Also worth naming: low-dose aspirin has the largest cardiovascular outcome literature of any over-the-counter agent, and current guidance has moved away from routine primary prevention because bleeding risk offsets benefit in lower-risk people. That is a clinical decision rather than a supplement one.

The general point: where a product has drug-like potency, it warrants drug-like caution, including interaction checking and monitoring.

What the Stack Cannot Do

This section is the honest centre of the article.

Dietary and supplement effects on apolipoprotein B are roughly an order of magnitude smaller than statin effects. In a person with elevated apoB, elevated lipoprotein(a), hypertension, established atherosclerosis or a strong family history, the outcome evidence for statins and antihypertensives is among the strongest in medicine, and no combination of the above matches it.

A person at genuine cardiovascular risk who chooses supplements over an indicated medication is making a decision the evidence does not support, and a platform that implied otherwise would be causing harm through omission.

What the stack legitimately does: adds modest apoB and triglyceride reduction alongside appropriate care, supports blood pressure where mineral intake is low, and covers the metabolic and inflammatory contributions that a lipid-lowering drug does not address.

The framing that works: supplements plus behaviour handle three of the four drivers of atherosclerosis, blood pressure, glycaemic function and inflammatory load, partially. Medication handles the fourth, particle burden, decisively. They are complements rather than alternatives.

The Behavioural Half, Which Is Larger

Not smoking. The largest single modifiable factor, by a wide margin.

Blood pressure control. Sodium reduction focused on processed food rather than the salt cellar, potassium from food, weight loss, aerobic exercise, alcohol reduction, and addressing sleep-disordered breathing, which causes resistant hypertension and is commonly missed.

Aerobic fitness. Among the strongest predictors of all-cause mortality in prospective data.

Visceral adiposity reduction. Improves lipids, glycaemia, blood pressure and inflammatory markers simultaneously.

Resistance training, for insulin sensitivity and lean mass.

Dietary pattern. Whole-diet quality outperforms any single nutrient manipulation, and the specific components that matter are less processed food, more fibre, more oily fish and adequate protein.

Sleep. Affects blood pressure and glycaemic control directly.

Each of these exceeds the stack's contribution, which is the ordering the Pillar 4 protocol follows.

Verifying It

Cardiovascular markers are measurable, so this stack can be audited.

Baseline: apolipoprotein B, lipoprotein(a) once, triglycerides and HDL, HbA1c, fasting insulin, hs-CRP, home blood pressure across a week, waist circumference, and a fitness estimate.

Re-measure at six to twelve weeks for triglycerides and apoB, which respond in that window, and at three to six months for HbA1c, hs-CRP and blood pressure.

Interpret against your own baseline rather than reference ranges, since reference ranges describe a population in which cardiovascular disease is the leading cause of death.

Draw conditions: away from acute illness and unaccustomed hard exercise for hs-CRP, fasting for triglycerides and insulin, and the same laboratory for comparison.

If apoB remains above target, that is a clinical conversation about medication rather than a reason for a longer supplement trial. This is where delay does the most damage, because the exposure is cumulative over decades and the years spent on an inadequate approach are not recoverable.